The Side Effects of Docetaxel with Cyclophosphamide As Postoperative Adjuvant Chemotherapy for Elderly Breast Cancer Patients

Lingqin Song,Yinbin Zhang,Jianjun He,Xijing Wang,Hongbing Ma,Wentao Xi,Liang

DOI: https://doi.org/10.1007/s10330-011-0815-6

2011-01-01

Abstract:The aim of this study was to investigate the side effects of docetaxel with cyclophosphamide as postoperative adjuvant chemotherapy for elderly breast cancer patients.

What problem does this paper attempt to address?

Patterns of Use of Docetaxel-Containing Adjuvant Chemotherapy among Chinese Patients with Operable Breast Cancer: A Multicenter Observational Study.

Hui Xie,Jinping Liu,Shiyou Yu,Yiding Chen,Min Zheng,Yongchuan Deng,Shu Wang,Jun Jiang,Yafen Li,Huiping Li,Hua Kang,Chunhui Zhang,Guo-Jun Zhang,Fengxi Su,Aiqun Cheng,Shui Wang

DOI: https://doi.org/10.1007/s12325-018-0841-7

2018-01-01

Advances in Therapy

Abstract:Adjuvant docetaxel-based chemotherapy is frequently used in the treatment of operable early breast cancer (EBC). This study investigated patterns of docetaxel use in patients with EBC in real-world clinical practice in China.
The Side Effects of TC Regimen As Post-Operative Adjuvant Chemotherapy for Breast Cancer Patients

SONG Lingqin,HE Jianjun,WANG Xijing,ZHANG Shuqun,LIANG Liang,ZHANG Yinbin

DOI: https://doi.org/10.3969/j.issn.1672-4992.2011.08.31

2011-01-01

Journal of Modern Oncology

Abstract:Objective:To investigate of the side effects TC regimen(Docetaxel 75mg/m2 with Cyclophosphamide 600mg/m2) as post-operative adjuvant chemotherapy for breast cancer patients.Methods: Total of 84 patients with breast cancer at intermediate risk based on the St Gallen risk classi?cation underwent modified radical mastectomy.Four cycles of TC regimen were administered at 3-week intervals after surgery.The side effects were evaluated.Results: The main side effect was neutropenia followed by nausea and vomiting.Cardiotoxicity and allergic reactions were not foudn.The difference in neutropenia incidence and dose reduction rate between patients younger than 65 years and aged 65 years or older was significant.Conclusion: Patients younger than 65 years can tolerate TC regimen at standard dose while ones aged 65 years or older need prophylaxis G-CSF or dose reduction.
Analysis of influencing factors for postoperative adjuvant chemotherapy effects in elderly patients with breast cancer

Chuan-dong MA,Xiao-song CHEN,Guang-yu LIU,Gen-hong DI,Jiong WU,Jin-song LU,Wen-tao YANG,Qi-xia HAN,Zhi-min SHAO,Zhen-zhou SHEN,Kun-wei SHEN

DOI: https://doi.org/10.3760/cma.j.issn.0254-9026.2009.04.011

2009-01-01

Abstract:Objective To explore the influencing factors for postoperative adjuvant chemotherapy effects in elderly patients with breast cancer. Methods Five hundred and ninety female patients aged 65 years or older with invasive breast cancer were treated in our hospital, and the influencing factors for postoperative adjuvant chemotherapy effects were analyzed by chi-square test and logistic regression. Results Two hundred and thirty-one (39.2%) patients received postoperative adjuvant chemotherapy. The results showed that diabetes, age, patterns of operation and pathological characteristics of tumor had significant influences on postoperative adjuvant chemotherapy effects (χ2=4.49,88. 27,23.49 and 9.40, all P<0.05). Logistic regression analysis showed that age, tumor size, lymph node status(pN) and estrogen receptor (ER) status were related to postoperative adjuvant chemotherapy effects(χ2=68.857,15. 284,43. 540 and 7.009 ,all P<0.01). Forty-four patients (66.7%) with pN(+)/ER(-) received adjuvant chemotherapy. Conclusions Age, tumor size, lymph node status and ER status were independent predictive factors for postoperative adjuvant chemotherapy effects in elderly patients with breast cancer.
Pharmacokinetics and safety of cyclophosphamide and docetaxel in a hemodialysis patient with early stage breast cancer: a case report

Liu Yang,Xiao-chen Zhang,Su-feng Yu,Hua-Qing Zhu,Ai-ping Hu,Jian Chen,Peng Shen

DOI: https://doi.org/10.1186/s12885-015-1932-3

IF: 4.638

2015-01-01

BMC Cancer

Abstract:Background Standardized chemotherapy used in cancer patients with severe kidney insufficiency is ineffective. Although there are some pharmacokinetic studies on cyclophosphamide in kidney insufficiency patients, to the best of our knowledge, the pharmacokinetics and safety of combination of cyclophosphamide and docetaxel as postoperative chemotherapy in a patient with early stage breast cancer undergoing hemodialysis is unclear thus far. Case Presentation The patient received regular TC regimen (cyclophosphamide 600 mg/m 2 , docetaxel 75 mg/m 2 ). She underwent hemodialysis 48 h after chemotherapy. Blood samples at multiple time-points were collected for determination of plasma levels of cyclophosphamide and docetaxel. Pharmacokinetic analyses indicated that compared with the reference data, the in vivo half-life (66.96 h) and drug exposure (150 %) of cyclophosphamide significantly increased; however, pharmacokinetic parameters of docetaxel was unaffected. Patient developed grade I thrombocytopenia and grade III leukopenia without any other severe adverse reactions. In total, four cycles of treatment were completed. After the chemotherapy, the patient received tamoxifen as endocrine therapy for one and a half years. No recurrence was reported. Conclusion These results suggest that the standard TC regimen is mostly safe and could be used as postoperative adjuvant chemotherapy for hemodialysis patients with early stage breast cancer.
Observation of Curative Effect of Adjuvant Chemotherapy in Elderly Patients with High-Risk StageⅡ and StageⅢColorectal Cancer after Radical Resection Surgery

俞春波,徐庆,陈锦先,陶淑芳

DOI: https://doi.org/10.3969/j.issn.1002-3429.2014.11.039

2014-01-01

Abstract:Objective To observe the efficacy and side effects of adjuvant chemotherapy in elderly patients with high-risk stage Ⅱ and stage Ⅲ colorectal cancer after radical resection surgery. Methods A total of 523 patients with high-risk stage Ⅱ and stage Ⅲ colorectal cancer were selected in our hospital during July 2011 and December 2012. With informed consent of the patients and their family members, they were divided into chemotherapy group (n=230) and non-chemotherapy group (n=293). The patients in chemotherapy group were assigned to receive FOLFOX regimen (fluorouracil plus oxaliplatin and calcium folinate) , XELOX regimen ( oxaliplatin plus capecitabine) or SOX regimen ( oxaliplatin plus S-1 capsule) . The difference of disease-free survival ( DFS) , tumor relapse and metastasis rates in two groups were analyzed one year and two years after surgery, and side effects of chemotherapy group were observed. Results All the patients completed the following up. Disease-free survival time of the chemotherapy group was longer than that of the non-chemotherapy group, the 2-year total relapse and metastasis rates of the chemotherapy group were lower than those of the non-chemotherapy group, and the 2-year disease-free survival rate of the chemotherapy group was higher than that of the non-chemotherapy group, and the differences were all statistically significant ( P<0. 05 ) . Kaplan-Meier survival analysis showed significant difference of 2-year DFS rate between the two groups (P<0. 05). Major adverse effects of the chemotherapy group were gastrointestinal disturbance, bone marrow suppression, liver dysfunction, peripheral neuropathy and hand-foot syndrome. After symptomatic treatment, all pa-tients could tolerate without effect of treatment. Conclusion Adjuvant chemotherapy maintains better efficacy in elderly pa-tients with high-risk stage Ⅱ and stage Ⅲ colorectal cancer after radical resection surgery, and could be better tolerated.
[Side Effects of Adjuvant Chemotherapy and Radiotherapy Concurrently after Conservative Surgery for Breast Cancer].

Peng Liu,De-qi Yang,Xin-min Qiao,Ying-ming Cao,Hong-jun Liu,Shu Wang,Lin Cheng

DOI: https://doi.org/10.3760/j:issn:0376-2491.2006.12.015

2006-01-01

Abstract:OBJECTIVE:Observe the side effects of adjuvant chemotherapy and radiotherapy concurrently after breast conservative surgery and investigate it feasible.METHODS:40 breast cancer patients of conservative surgery were divided into two groups randomizedly, 20 patients of the study group were given adjuvant chemotherapy and radiotherapy concurrently, 20 patients of the control group were given adjuvant thermotherapy and radiotherapy sequently. Observe the side effects of the patients in the two groups and follow them 6 months.RESULTS:The leukopenia within the third chemotherapeutic cycle and the oral mucitis within the fourth chemotherapeutic cycle in the study group were more severe than those in the control group (P < 0.05). The other side effects within every chemotherapeutic cycles were similar in both groups, including skin reaction in radiotherapeutic area, gastroenteric reaction, alopecia, arthralgia, neurotoxicity and abnormal hepatic function. Following the patients of the two groups in 6 months, there were no significance in hemogram, hepatic and renal function, electrocardiogram and chest x-ray.CONCLUSION:It is feasible and safe to give the adjuvant chemotherapy and radiotherapy concurrently to the breast cancer patients after conservative surgery.
The effect of adjuvant chemotherapy on symptom burden and quality of life over time; a preliminary prospective observational study using individual data of patients aged ≥70 with early stage invasive breast cancer

Chantal Quinten,C Kenis,M Hamaker,A Coolbrandt,B Brouwers,L Dal Lago,P Neven,P Vuylsteke,G Debrock,H Van Den Bulck,A Smeets,P Schöffski,A Bottomley,U Wedding,H Wildiers

DOI: https://doi.org/10.1016/j.jgo.2017.10.001

Abstract:Objectives: We aim to assess short and long term effects of chemotherapy on patient-reported quality of life (QOL) and patient versus clinician symptom reporting in older patients with breast cancer adjusted for tumour and aging parameters. Material and methods: In this prospective, multicentre, non-interventional, observational study, women aged ≥70years were enrolled after surgery and assigned to a TC chemotherapy (docetaxel and cyclophosphamide) group or a control group depending on their planned adjuvant treatment. Longitudinal multivariate models were used to assess the statistical and minimal clinically important difference (MCID) in the impact of TC chemotherapy over time on QOL and symptom burden adjusted for baseline aging and tumour parameters. Statistical significance was set at 5% and MCID at 10 points. Results: In total, 57 patients were enrolled in the chemotherapy and 52 patients in the control group. Within the chemotherapy group, clinical deterioration was reported at 3months for Fatigue (17.73), Dyspnoea (17.05), Diarrhoea (12.06) and Appetite Loss (17.05) scores (all p<0.001). However, the scores had returned to baseline (or even better for Role Functioning) at year 1. No clinical deterioration was reported in the control group. Symptom scores as reported by patients were significantly (p<0.05) higher than those reported by the clinicians, even more so for Fatigue, Dyspnoea, and Pain. Conclusion: Our results show that symptom burden and diminished QOL in an older breast cancer population receiving adjuvant TC chemotherapy are short-lived and disappear after a while with no long-term differences compared to a similar population not receiving chemotherapy.
Adjuvant chemotherapy for elderly patients with NSCLC

ZHOU Zhen,CHEN Zhi-wei,LU Shun,HOU Xue

DOI: https://doi.org/10.16073/j.cnki.cjcpt.2010.09.017

2010-01-01

Abstract:OBJECTIVE:To undsrstand the effect of the cisplatin-based adjuvant chemotherapy on a consistent survival for elderly patients with NSCLC.METHODS:A total of 314 elderly resected patients with NSCLC were enrolled from Jan.2001 to Dec.2004,and retrospectively analyzed the effect of the adjuvant chemotherapy on survival and compared the treatment characteristics and chemotherapy toxicity of 3 groups:65-70 yr.(younger),70-75 yr.(elderly)and ≥75 yr.(more elderly).RESULTS:Only 29.9% elderly patients received the adjuvant chemotherapy,and adjuvant chemotherapy showed no significant survival for elderly patients(P=0.636 5),and the median survival time was(39.4±8.39)and(25.70±6.83)months.If the patients finished 3 cycles or 4,they had a significant survival benefit than those did not(P=0.033 6),and the median survival time was(86.60±26.99)months and(23.40±6.01)months,respectively,reducing the mortality risk(P=0.002,HR=0.806).The COX multivariate analysis showed that age was not a factor influencing the survival,only the pathological staging and cisplatin-based chemotherapy(≥3 cycles)were the factors influencing the survival.CONCLUSION:The cisplatin-based adjuvant chemotherapy for selected elderly resected patients with lung cancer who can be expected to finish 3 cycles or more have a significantly suvival,reducing the mortality risk.
Impact of Adjuvant Chemotherapy in Elderly Breast Patients in Taiwan, A Hospital-Based Study

Hsiu-Chuan Lee,Wei-Yu Chen,Wen- Tsung Huang,Kuo- Chen Cheng,Yu-Feng Tian,Chung-Han Ho,Chao- Jung Tsao,Yin- Hsun Feng

DOI: https://doi.org/10.22034/apjcp.2016.17.10.4591

2016-10-01

Abstract:Purpose: Decisions as to whether to provide adjuvant treatment in older breast cancer patients remains challenging. Side effects of chemotherapy have to be weighed against life expectancy, comorbidities, functional status, and frailty. To aid decision-making, we retrospectively analyzed 110 women with breast cancer treated with a curative intention from 2006 to 2012. Survival data with clinical and pathological parameters were evaluated to address the role of adjuvant chemotherapy in this study population. Method: A total of 110 elderly (>70 years) patients that received mastectomy at two hospitals in Taiwan were observed retrospectively for a medium of 51 months. After mastectomy, patients received conservative treatment or adjuvant chemotherapy, or hormone therapy following clinical guidelines or physician’s preference. Data were collected from the cancer registry system. Results: Median age at diagnosis was 75.7 years. Thirty-five percent of patients received adjuvant chemotherapy, these having a significantly younger age (mean=74.0±5.3 vs 77.5±5.3, p<0.001) and higher tumor staging (p=0.003) compared with their non-chemotherapy counterparts.Five-year overall survival was non-significantly higher in patients who received adjuvant chemotherapy (with chemotherapy 64.2% vs without chemotherapy 62.6%, p=0.635), while five-year recurrence free survival was non-significantly lower (with chemotherapy 64.1% vs without chemotherapy 90.5%, p=0.80). Conclusions: In this analysis, adjuvant chemotherapy tended to be given to patients with a younger age and higher tumor staging at our institute. It was not associated with any statistically significant improvement in survival and recurrence rate. Until age specific recommendations are available, physicians must use their clinical judgment and assess the tumor biology with the patient’s comorbidities to make the best choice. Clinical trials focusing on this critical issue are warranted.
Clinical study on docetaxel combined with rh-endostatin in treatment of elderly advanced non-small cell lung cancer

Hong-ming FANG,Xin-min YU,Xun SHI,Yu WAN,Feng CHAI,Wei HONG,Yi-ling JIANG,Jian-xiong LIU,Mei-wen HE

2010-01-01

Abstract:OBJECTlVE: To evaluate the efficacy and safety of docetaxel combined with rh-endostatin (Endostar) in the treatment of elderly advanced non-small cell lung cancer (NSCLC). METHODS : Sixty old patients with advanced NSCLC were divided into a treatment group and control group. In the treatment group, the patients received Endostar (15 mg, iv, d 1 -d 14 ) combined with docetaxel (35 mg/m 2, iv, d 1 , d 8) as first line treatment, and in the control group, the patients received docetaxel (35 mg/m 2, iv, d 1 ,d 8) as first line treatment. For 2 or 4 cycles, the efficacy and toxicity of the two groups were evaluated. RESULTS:In the treatment group, the response rate was 46. 7%, the disease control rate was 73. 3%, and the median time to progress was 4. 5 months;the control group, the response rate was 23. 3%, the disease control rate was 56. 6%, and the median time to progress was 3. 2 months. There was a significant difference between the two groups (P<0. 05), but there was no significant difference in quality of life between the two groups (P>0. 05). The major adverse effects were neutropenia, liver and renal function damage, nausea and vomiting. CONCLUSIONS: Endostar combined with docetaxel in the treatment of elderly advanced NSCLC can improve the objective response rate and prolong the time to disease progress compared with the simple chemotherapy and without toxicity increasing. This therapy is well tolerated, safe and effective for elderly advanced NSCLC, so it is worthy of further clinical study.
The effect of docetaxel on immunological function of patients with metastatic breast cancer

Bin SHAO,Hui-ping LI,Guo-hong SONG,Li-jun DI,Han-fang JIANG,Ying YAN,Huan WANG,Feng-ling WAN,Miao-ning YOU

DOI: https://doi.org/10.11877/j.issn.1672-1535.2016.14.12.06

2016-01-01

Abstract:Objective To explore the change of lymphocytes subsets ratio in peripheral blood of patients with meta-static breast cancer (MBC) before and after chemotherapy with docetaxel and the influence factors. Method The ratio of lymphocyte subsets (CD3+T cell, CD3+/CD4+T cell, CD3+/CD8+T cell, CD3-/CD16+56+NK cell, CD3+/CD16+56+T cell, CD19+B cell, CD4+/CD25+T cell,CD8+/CD28-T cell, CD8+/CD28+T cell) in peripheral blood of 34 MBC patients were analyzed with flow cytometry before and after chemotherapy. The result was analyzed in combination with patients’clini-copathological characteristics. Result The ratio of CD3+T cell, CD3+/CD4+T cell and CD19+B cell decreased signifi-cantly after two cycles of docetaxel chemotherapy (P=0.002, 0.044, 0.006) in all the 34 patients, with decreases of 2.2%, 4.7%and 3.1%, respectively. The patients at age>54 years (median) had less CD19+B lymphocytes decrease compared with those at age≤54 years (P=0.031);while the patients with overall survival (OS)>33.6 months had less CD3+T lym-phocytes decrease compared with those with OS ≤33.6 months (P=0.038). Conclusion Docetaxel chemotherapy de-creased the ratio of T and B lymphocyte as well as the immunological function of MBC patients, and relatively better re-tention of T cell immunological function might offer better survival benefit.
Safety Analysis of Adjuvant Chemotherapy with Docetaxel Administered with or without Anthracyclines to Early Stage Breast Cancer Patients: Combined Results from the Asia- Pacific Breast Initiatives I and II.

Sung Bae Kim,Ahmed Sayeed,Antonio H Villalon,Zhen Zhou Shen,Tsz Kok Yau,Mazhar Ali Shah,Meng Feng Hou,Tran Van Thuan,Duc Nguyen Ba,Tsu-Yi Chao

DOI: https://doi.org/10.7314/apjcp.2016.17.2.697

2016-01-01

Asian Pacific Journal of Cancer Prevention

Abstract:The safety parameters of adjuvant docetaxel therapy used to treat sequential Asian women were comparable to those reported in clinical trials evaluating the role of adjuvant docetaxel. No unusual adverse events linked to Asia-Pacific region patients were observed.
Clinical Observation of Xeloda plus Oxaliplatin in the Treatment of the Elderly Patients with Advanced Colorectal Cancer

Ding Lingchi,Tian Siyuan,Lu Junguo,Yao Weidong,Zhang Xiaodong

DOI: https://doi.org/10.3969/j.issn.1673-5412.2012.05.004

2012-01-01

Abstract:Objective To evaluate the efficacy and toxicities of xeloda plus oxaliplatin in the treatment of the elderly patients with advanced colorectal cancer.Methods A total of 28 elderly patients with advanced colorectal cancer received the chemotherapy,oxaliplatin 130 mg·m-2 on day 1;xeloda 1 000 mg·m-2 on days 1-14,every 3 weeks as a cycle,the efficacy was evaluated after 2 cycles of chemotherapy.Results Of the 28 patients,CR was observed in the 1 case(3.6%),PR was observed in the 12 cases(42.9%),SD was observed in the 11 cases(39.3%),PD was observed in the 4 cases(14.3%),the overall response rate was 46.4%,the median time to tumor progress was 7.3 months.The common toxicities were marrow depression,gastrointestinal reaction,peripheral neurotoxicity and hand-foot syndrome.Conclusion The xeloda plus oxaliplatin is effective and safe for the elderly patients with advanced colorectal cancer.
The evaluations of different age advanced non-small-cell lung cancer patients treated with docetaxel plus platinum combination chemotherapy

LI Zi-ming,BI Kang-ning,LIAO Mei-lin,CHEN Wen,LU Shun

2006-01-01

Chinese Clinical Oncology

Abstract:Objective:To compare the elder(≥70) with younger(<70) advanced non-small-cell lung cancer (NSCLC) patients treated with docetaxel plus platinum in survival time, toxicity, costs and hospital-days.Methods:Using χ2 test, Kaplan-Meier method and COX regression analysis to compare the effect of age in NSCLC patients.Results:46 advanced NSCLC patients in Shanghai Chest Hospital were retrospectively reviewed during April 2002 to December 2004. All patients had received docetaxel plus platinum chemotherapy. elderly NSCLC patients appeared to be similar to those younger patients in survival (χ2=0.41, P=0.522 7), hematologic toxicity (χ2=1.963, P=0.274), nonhematologic toxicity (χ2=1.414; P=0.344), costs(χ2=0.657, P=0.699) and hospital-days (χ2=0.634, P=0.480) . COX regression analysis demonstrated KPS had effect on survival (P=0.008 and P=0.014 respectively).Conclusion:Elderly NSCLC patients seemed to be well tolerated to docetaxel plus platinum chemotherapy.
Adjuvant Chemotherapy for Breast Cancer in Older Adult Patients

Ying Gao,Jie Hao,Zhendong Zhang

DOI: https://doi.org/10.2147/CIA.S470262

2024-07-16

Abstract:Decision-making regarding adjuvant chemotherapy for older adults with breast cancer is a challenge because older adult patients often have poor physical health, frailty, and age-related comorbidities, which can compromise treatment outcome. Due to these considerations, doctors tend to use less chemotherapy for breast cancer in older adults. However, older patients in good general health could still benefit from chemotherapy. Careful benefit-risk assessment is essential to provide best care for each older adult patient. Due to a rapidly aging population, breast cancer in older adults is becoming a serious public health issue in China. In this mini review, we discuss the need, means, and tools to assess the benefits and risks of adjuvant chemotherapy in older adults with breast cancer. The contents of this review may drive decision-making with regard to the use and selection of adjuvant chemotherapy for older adult patients in China who are fit for the treatment.
Safety Results of Docetaxel-(Taxotere®)-Based Chemotherapy in Early Breast Cancer Patients of Asia-Pacific Region: Asia-Pacific Breast Initiative II

Sung-Bae Kim,Yau Tsz Kok,Tran Van Thuan,Tsu-Yi Chao,Zhen Zhou Shen

DOI: https://doi.org/10.4048/jbc.2015.18.4.356

2015-01-01

Journal of Breast Cancer

Abstract:Purpose The goal of this registry was to collect patient characteristics and safety data from patients from the Asia-Pacific region with early breast cancer receiving adjuvant chemotherapy containing docetaxel (Taxotere®). Methods This registry was open-label, international, longitudinal, multicenter, and observational in design and included a prospective group of consecutive early breast cancer patients with an intermediate-to-high risk of recurrence being treated with various docetaxel-based (anthracycline and non-anthracycline) adjuvant chemotherapy regimens during 2009-2013 in real-world clinical settings. Results The analysis included 1,712 patients, 79% of whom received docetaxel-based, anthracycline-containing regimens, while 21% received non-anthracycline-containing regimens. Patients receiving adjuvant docetaxel-based chemotherapy were followed for 1.5 years. Chemotherapy-related adverse events (AEs) were reported by 76.2% of patients (anthracycline-containing vs. non-anthracycline-containing regimens: 76.8% vs. 74.1%). Serious AEs were reported in 12% of patients (12.3% vs. 10%). National Cancer Institute Common Terminology Criteria for Adverse Events grade 3 or higher neutropenia was reported in 20% of patients (21.6% vs. 13.9%), leukopenia in 7.4% of patients (5.4% vs. 14.8%), and vomiting in 1.6% of patients (1.8% vs. 0.6%). Treatment-related death was reported in 27 patients (1.6%), while only 3% of patients had a relapse. Low-density lipoprotein cholesterol/high-density lipoprotein cholesterol (HDL-C) and total cholesterol/HDL-C ratios increased after chemotherapy. A clinically insignificant reduction of 1.9% in left ventricular ejection fraction, from 66.43 to 64.53, was observed 1.5 years after therapy was completed. Conclusion The Asia-Pacific Breast initiative II registry identified a variety of important facts regarding patient population characteristics, disease epidemiology and treatment response for early breast cancer patients of the Asia-Pacific region receiving docetaxel-based chemotherapy. Docetaxel-based chemotherapy did not show any significant safety concerns for early breast cancer patients of the Asia-Pacific region, and thus may represent a safe adjuvant chemotherapy regimen for these patients.
Cbcsg-10: Adjuvant Capecitabine in Combination with Docetaxel and Cyclophosphamide Plus Epirubicin for Triple Negative Breast Cancer.

Shao Zhimin,Junjie Li,Da Pang,Changqing Wang,Jun Jiang,Suisheng Yang,Yunjiang Liu,Pei Fen Fu,Yuan Sheng,Guojun Zhang,Liya Cao,Qi He,Shude Cul,Xijing Wang,Guosheng Ren,Xinzheng Li,Shiyou Yu,Pengxi Liu,Binghe Xu,Xi-Chun Hu

DOI: https://doi.org/10.1200/jco.2016.34.15_suppl.1012

IF: 45.3

2016-01-01

Journal of Clinical Oncology

Abstract:1012Background: Standard adjuvant chemotherapy regimens for triple-negative breast cancer (TNBC) contain taxane and anthracycline. We aimed to investigate the efficacy and safety of integrate capecitabine in the adjuvant treatment of triple-negative patients. Methods: For this randomized, open-label, phase 3 trial undertaken at 35 institutions or hospitals in China, we recruited women with early TNBC after surgery. Eligible patients were randomly assigned (1:1) using a central patient screening and randomization system to either three cycles of capecitabine and docetaxel (TX) followed by three cycles of cyclophosphamide, epirubicin, and capecitabine (XEC), or to three cycles of docetaxel (T) followed by three cycles of cyclophosphamide, epirubicin, and fluorouracil (FEC). The primary endpoint was disease-free survival (DFS). This trial is registered with ClinicalTrials.gov, number NCT01642771. Results: Between Jun, 2012, and Nov, 2013, 585 patients were assessed for eligibility and randomized. 288 patient...
Clinical and Pathological Characteristics and Treatment of Elderly Patients with Breast Cancer

Chuan-Dong Ma,Xiao-Song Chen,Guang-Yu Liu

DOI: https://doi.org/10.3321/j.issn:0529-5815.2008.18.012

2008-01-01

Abstract:OBJECTIVE:To explore the clinical and pathological characteristics and treatment patterns and the factors influencing treatments of elderly patients with breast cancer.METHODS:From January 2001 to December 2006, 647 female breast cancer patients over 65 years old were treated. The clinical records were reviewed. All patients were divided into three groups according to age, including 65 to 69 years old group, 70 to 74 years old group and 75 years or elder group. These 647 patients accounted for 13.4% of all breast cancer patients undergoing surgery during the same period. Major pathological type was invasive ductal carcinoma (79.3%). The patients who had chronic comorbid diseases of other systems accounted for 54.7%. Five hundred and eighty-six patients underwent modified radical mastectomy, accounting for 90.6%. Two hundred and thirty-three patients underwent postoperative adjuvant chemotherapy, accounting for 36.0%. The differences of clinicopathological characteristics and treatment patterns between three groups were tested by Chi-square test.RESULTS:Older patients had more tumors with mucinous and other pathological types, less over-expression of Her2/Neu(+++), higher probability to have comorbidities, higher probability to undergo relatively conservative surgery, lower probability to receive postoperative chemotherapy, and higher probability to receive postoperative endocrine therapy alone.CONCLUSIONS:Breast cancer in the elderly exhibits distinctive clinical and pathological characteristics. Treatment patterns they received are related to age.
The impact of adjuvant chemotherapy in older breast cancer patients on clinical and biological aging parameters

Barbara Brouwers,Sigrid Hatse,Lissandra Dal Lago,Patrick Neven,Peter Vuylsteke,Bruna Dalmasso,Guy Debrock,Heidi Van Den Bulck,Ann Smeets,Oliver Bechter,Jithendra Kini Bailur,Cindy Kenis,Annouschka Laenen,Patrick Schöffski,Graham Pawelec,Fabrice Journe,Ghanem-Elias Ghanem,Hans Wildiers

DOI: https://doi.org/10.18632/oncotarget.8796

2016-05-24

Oncotarget

Abstract:Purpose: This prospective observational study aimed to evaluate the impact of adjuvant chemotherapy on biological and clinical markers of aging and frailty. Methods: Women ≥ 70 years old with early breast cancer were enrolled after surgery and assigned to a chemotherapy (Docetaxel and Cyclophosphamide) group (CTG, n=57) or control group (CG, n=52) depending on their planned adjuvant treatment. Full geriatric assessment (GA) and Quality of Life (QoL) were evaluated at inclusion (T0), after 3 months (T1) and at 1 year (T2). Blood samples were collected to measure leukocyte telomere length (LTL), levels of interleukin-6 (IL-6) and other circulating markers potentially informative for aging and frailty: Interleukin-10 (IL-10), Tumor Necrosis Factor Alpha (TNF-α), Insulin-like Growth Factor 1 (IGF-1), Monocyte Chemotactic Protein 1 (MCP-1) and Regulated on Activation, Normal T cell Expressed and Secreted (RANTES). Results: LTL decreased significantly but comparably in both groups, whereas IL-6 was unchanged at T2. However, IL-10, TNF-α, IGF-1 and MCP-1 suggested a minor biological aging effect of chemotherapy. Clinical frailty and QoL decreased at T1 in the CTG, but recovered at T2, while remaining stable in the CG. Conclusions: Chemotherapy (TC) is unlikely to amplify clinical aging or induce frailty at 1 year. Accordingly, there is no impact on the most established aging biomarkers (LTL, IL-6).
<TITLE>CLINICAL ANALYSIS OF PRE-OPERATIVE NEOADJUVANT CHEMOTHERAPY IN ELDERLY PATIENTS WITH ADVANCED BREAST CANCER

Jiang Yiming,Kong Lei,Han Feng,Chen Teng

DOI: https://doi.org/10.3969/j.issn.1008-8296.2006.02.020

2006-01-01

Abstract: objective To investigate the effect of elderly patients with advanced breast cancer after pre-operative neoadjuvant chemotherapy. methods A total of 23 patients with advanced breast cancer underwent the TA neoadjuvant chemotherapy for 2~3 cycles before operation. results The total response rate was 82.6% (19/23), including no change (NC, n=4), partial response (PR, n=8), mild response (MR, n=11), complete response (CR, n=0). Pathologic changes of neoplasm, such as degeneration, necrosis, fibrosis, inflammatory infiltration, were observed after neoadjuvant chemotherapy. Conclusions Pre-operative neoadjuvant chemotherapy in the treatment of advanced breast cancer may destroy large number of tumor cells vigorously, diminish the primary lesion, make the tumor stage down, increase curative resection and long term survival rate.

The Side Effects of Docetaxel with Cyclophosphamide As Postoperative Adjuvant Chemotherapy for Elderly Breast Cancer Patients

Patterns of Use of Docetaxel-Containing Adjuvant Chemotherapy among Chinese Patients with Operable Breast Cancer: A Multicenter Observational Study.

The Side Effects of TC Regimen As Post-Operative Adjuvant Chemotherapy for Breast Cancer Patients

Analysis of influencing factors for postoperative adjuvant chemotherapy effects in elderly patients with breast cancer

Pharmacokinetics and safety of cyclophosphamide and docetaxel in a hemodialysis patient with early stage breast cancer: a case report

Observation of Curative Effect of Adjuvant Chemotherapy in Elderly Patients with High-Risk StageⅡ and StageⅢColorectal Cancer after Radical Resection Surgery

[Side Effects of Adjuvant Chemotherapy and Radiotherapy Concurrently after Conservative Surgery for Breast Cancer].

The effect of adjuvant chemotherapy on symptom burden and quality of life over time; a preliminary prospective observational study using individual data of patients aged ≥70 with early stage invasive breast cancer

Adjuvant chemotherapy for elderly patients with NSCLC

Impact of Adjuvant Chemotherapy in Elderly Breast Patients in Taiwan, A Hospital-Based Study

Clinical study on docetaxel combined with rh-endostatin in treatment of elderly advanced non-small cell lung cancer

The effect of docetaxel on immunological function of patients with metastatic breast cancer

Safety Analysis of Adjuvant Chemotherapy with Docetaxel Administered with or without Anthracyclines to Early Stage Breast Cancer Patients: Combined Results from the Asia- Pacific Breast Initiatives I and II.

Clinical Observation of Xeloda plus Oxaliplatin in the Treatment of the Elderly Patients with Advanced Colorectal Cancer

The evaluations of different age advanced non-small-cell lung cancer patients treated with docetaxel plus platinum combination chemotherapy

Adjuvant Chemotherapy for Breast Cancer in Older Adult Patients

Safety Results of Docetaxel-(Taxotere®)-Based Chemotherapy in Early Breast Cancer Patients of Asia-Pacific Region: Asia-Pacific Breast Initiative II

Cbcsg-10: Adjuvant Capecitabine in Combination with Docetaxel and Cyclophosphamide Plus Epirubicin for Triple Negative Breast Cancer.

Clinical and Pathological Characteristics and Treatment of Elderly Patients with Breast Cancer

The impact of adjuvant chemotherapy in older breast cancer patients on clinical and biological aging parameters

<TITLE>CLINICAL ANALYSIS OF PRE-OPERATIVE NEOADJUVANT CHEMOTHERAPY IN ELDERLY PATIENTS WITH ADVANCED BREAST CANCER